No treatment-related deaths were observed.<h4>Conclusion</h4>In routine clinical practice, cetuximab combined with platinum-based chemotherapy remains an effective and well-tolerated first-line treatment for R/M HNSCC, particularly in patients who are ineligible for immunotherapy or with PD-L1-negative tumors. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.